Paid Clinical Trials in Midlothian, VA
As of July 2026, 53 paid clinical trials are recruiting in Midlothian, Virginia. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Midlothian offers studies at sites including Bon Secours Saint Francis Medical Center for conditions such as Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8, Breast Neoplasms, Malignant Solid Neoplasm. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Midlothian
Trials by drug in Midlothian
Filter results
Newly added in Midlothian
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
53 clinical trials
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Mobile Health for Adherence in Breast Cancer Patients
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
E-Mindfulness Approaches for Living After Breast Cancer
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
TERPS Trial for de Novo Oligometastic Prostate Cancer
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Top Research Study Locations in Midlothian
Researchers run research studies in Midlothian, VA at 13 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Bon Secours Saint Francis Medical Center | Anatomic Stage II Breast Cancer AJCC v8, Breast Cancer, Malignant Solid Neoplasm | 28 |
| Bon Secours Westchester Emergency Center | Breast Cancer, Malignant Solid Neoplasm, Acute Lymphoblastic Leukemia | 7 |
| Bon Secours Cancer Institute at St. Francis | Breast Cancer, Oligometastatic Disease, Prostate Cancer | 4 |
| Bon Secours St. Francis Medical Center | Breast Neoplasms, Colo-rectal Cancer | 3 |
| Bon Secours Cancer Institute at Saint Francis | Metastatic Castration-resistant Prostate Cancer | 1 |
| Bon Secours Cardiology | Cardiovascular Disease | 1 |
| Bon Secours Memorial Regional Medical Center-Oncology Research Department | Triple-Negative Breast Cancer | 1 |
| Bon Secours St. Francis Medical Center-Oncology Research | Breast Neoplasms | 1 |
| Bon Secours St. Francis Medical Oncology Center | Breast Cancer | 1 |
| Bon Secours St. Marys | Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Ventricular Arrhythmia | 1 |
| Bon Secours Virginia Health System | Early Breast Cancer | 1 |
| Tekton Research | Type 2 Diabetes | 1 |
| Virginia Cancer Institute | Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases | 1 |
Active & Upcoming Studies in Midlothian (2026)
Recruiting trials in Midlothian grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (39 active studies)
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer · Phase 3 · AstraZeneca
- A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) · Phase 2 · NSABP Foundation Inc
Cardiovascular (2 active studies)
- Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin · Phase 3 · AstraZeneca
- Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias · Heart Rhythm Clinical and Research Solutions, LLC
Mental health & behavior (1 active study)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
Diabetes & metabolic (1 active study)
- HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes · Phase 2 · Housey Healthcare ULC
Common conditions studied in Midlothian
- Breast Cancer (6 active studies)
- Anatomic Stage II Breast Cancer AJCC v8 (4 active studies)
- Breast Neoplasms (4 active studies)
- Malignant Solid Neoplasm (3 active studies)
- Stage IVA Prostate Cancer AJCC v8 (3 active studies)
- Anatomic Stage I Breast Cancer AJCC v8 (2 active studies)
Leading research sponsors in Midlothian
- NRG Oncology
- AstraZeneca
- Alliance for Clinical Trials in Oncology
- SWOG Cancer Research Network
- Merck Sharp & Dohme LLC
Frequently asked questions
How many paid clinical trials are currently recruiting in Midlothian?
There are approximately 53 recruiting clinical trials in Midlothian, Virginia listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Midlothian pay participants?
Most recruiting trials in Midlothian compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Midlothian?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Midlothian?
The most common conditions under active study in Midlothian include Breast Cancer (6), Anatomic Stage II Breast Cancer AJCC v8 (4), Breast Neoplasms (4), Malignant Solid Neoplasm (3), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Midlothian?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Midlothian on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Midlothian?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Midlothian?
Recruiting research sites in Midlothian include Bon Secours Saint Francis Medical Center, Bon Secours Westchester Emergency Center, Bon Secours Cancer Institute at St. Francis, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Midlothian right now?
The largest active categories in Midlothian are Cancer & tumors (39), Cardiovascular (2), Mental health & behavior (1). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.